Abstract
Thrombosis of the heart valve prothesis with subsequent possible cerebrovascular or systemic thromboembolism are life-threatening clinical conditions. Surgical replacement (or plastic – reconstruction procedure especially in mitral valve failure) of a damaged heart valve remains the standard method of treatment with the classic indication of anticoagulant therapy – lifelong (artificial mechanical prostheses) or temporary (cardiac bioprotheses). In recent years, transcatheter techniques are increasingly being used, especially in patients at higher surgical risk, including elderly patients who have increased morbidity and mortality and different etiologies of valve defects. Properly managed anticoagulant therapy is crucial for reducing morbidity and mortality of the patients (Tab. 6,  Ref. 40). Text in PDF www.lekarskyobzor.sk.
KEY WORDS: heart valve replacement, thrombosis, anticoagulant treatment.

Lek Obz 2022, 71 (6 – 7): 258-264

Vasiľ HRICÁK, Jr., Miriam PETROVÁ, Róbert VOJTKO

Ústav farmakológie a klinickej farmakológie, Lekárska fakulta UK v Bratislave, prednosta prof. M. Wawruch, PhD.

Cite:

HRICÁK, V. jr., PETROVÁ M., VOJTKO R.: Heart valve replacement and current anticoagulant management. Lek Obz 2022, 71 (6 – 7): 258-264